BRIEF RESEARCH REPORT article
Front. Allergy
Sec. Asthma
Volume 6 - 2025 | doi: 10.3389/falgy.2025.1676399
Allergen Immunotherapy for the Control of Moderate to Severe Allergic Asthma: An Evidence-based Conjoint Analysis to Define Candidate Patient Profiles in Spain and Portugal
Provisionally accepted
- 1Hospital Universitario Virgen Macarena, Seville, Spain
- 2Hospital Universitario Virgen del Rocio, Seville, Spain
- 3Hospital Clinic of Barcelona, Barcelona, Spain
- 4Hospital Universitario La Paz, Madrid, Spain
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Allergen immunotherapy (AIT) is an effective and safe treatment; however, it is not recommended in consensus guidelines for severe allergic asthma patients. As AIT has been shown to be capable of modifying the course of the disease, it should be considered a concomitant treatment for specific asthma patients. This study aimed to define the profile of patients with severe allergic asthma who are most likely to benefit from AIT. Methods: A conjoint analysis approach was adopted to comprehensively assess the importance of clinical attributes in therapeutic decision-making. A scientific committee selected the main attributes to be considered: lung function, clinical control of allergic asthma, current main treatment and etiological confirmation of moderate to severe allergic asthma. Using the fractional factorial analysis technique, 8 eligible patient profiles for AIT were defined. Participant allergists, by means of a questionnaire, classified the profiles in order of preference, mimicking the comprehensive assessment performed in clinical practice. Results: 91 allergists from Spain and Portugal with experience in asthma and AIT participated in the study. Allergists gave greater importance to the clinical control of allergic asthma (relative importance of 51.6%), followed by preserved lung function (relative importance of 25.0%), confirming that the most important criterion was good control of the underlying asthmatic condition. Conclusions: The expert allergists endorse the use of AIT in the management of moderate to severe allergic asthma in patients with appropriate clinical characteristics. Additional studies to further investigate the safety and effectiveness of this new therapeutic approach would be of interest.
Keywords: Severe allergic asthma, allergen immunotherapy, AIT, Conjoint Analysis, patientprofiling, Etiological treatment
Received: 30 Jul 2025; Accepted: 07 Oct 2025.
Copyright: © 2025 Delgado, Cárdenas, Gelis and Domínguez-Ortega. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Sònia Gelis, gelis@clinic.cat
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.